doi:10.19982/j.issn.1000-6621.20260006

Abstract

CLC Number:

R521
R758.25

References 18

[1]	Jin H J, Kang D Y, Nam Y H, et al. Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients[J]. Allergy Asthma Immunol Res, 2021, 13(2):245-255. doi:10.4168/aair.2021.13.2.245.
[2]	Gunter H M, Choshi P, Chimbetete T, et al. Genetic polymorphisms and adverse reactions to antituberculosis therapy[J]. Pharmacogenomics, 2025, 26(5-6):207-221. doi:10.1080/14622416.2025.2509479. pmid: 40538374
[3]	Datta A, Sivasankar R, Kar B R. Pyrazinamide-induced Toxic Epidermal Necrolysis[J]. Ann Afr Med, 2024, 23(3):494-495. doi:10.4103/aam.aam_161_23. pmid: 39034578
[4]	Gibson A, Deshpande P, Campbell C N, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions[J]. J Allergy Clin Immunol, 2023, 151(2):289-300.e4. doi:10.1016/j.jaci.2022.12.005. pmid: 36740326
[5]	Heuer R, Paulmann M, Mockenhaupt M, et al. Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta-analysis[J]. J Dtsch Dermatol Ges, 2026, 24(1):34-42. doi:10.1111/ddg.15804.
[6]	Shah H, Parisi R, Mukherjee E, et al. Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management[J]. Am J Clin Dermatol, 2024, 25(6):891-908. doi:10.1007/s40257-024-00889-6. pmid: 39278968
[7]	Justice J, Mukherjee E, Martin-Pozo M. Updates in the pathogenesis of SJS/TEN[J]. Allergol Int, 2025, 74(3):361-371. doi:10.1016/j.alit.2025.05.002. pmid: 40473510
[8]	中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5):376-381. doi:10.35541/cjd.20201177.
[9]	Katran Z Y, Bulut I, Babalik A, et al. Treatment and management of hypersensitivity reactions developed against anti-tuberculosis drug[J]. Int J Mycobacteriol, 2022, 11(3):309-317. doi:10.4103/ijmy.ijmy_78_22. pmid: 36260451
[10]	吕艳思, 王彬, 关律昕, 等. 大疱性类天疱疮免疫相关治疗新进展[J]. 皮肤性病诊疗学杂志, 2025, 32(11):830-836. doi:10.3969/j.issn.1674-8468.2025.11.011.
[11]	Swami A, Gupta B, Bhattacharjee P. Response to Modified Antitubercular Drug Regime and Antiretroviral Therapy in a Case of HIV Infection with Disseminated Tuberculosis with Isoniazid Induced Toxic Epidermal Necrolysis[J]. Case Rep Infect Dis, 2012, 2012:626709. doi:10.1155/2012/626709.
[12]	胡少瑜, 冯艳仪, 戚振红. 左氧氟沙星抗结核治疗致中毒性表皮坏死松解症1例报道[J]. 新发传染病电子杂志, 2026, 11(2):66-70. doi:10.19871/j.cnki.xfcrbzz.2026.02.013.
[13]	Chen C B, Hung S I, Chang J W, et al. Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade[J]. Nat Commun, 2024, 15(1):10733. doi:10.1038/s41467-024-54180-7.
[14]	Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Br J Dermatol, 2010, 163(4):847-853. doi:10.1111/j.1365-2133.2010.09863.x.
[15]	Lestari W, Vella V, Yasir T, et al. Case Report: A successful case of toxic epidermal necrolysis treated with plasmapheresis therapy[J]. F1000Res, 2022, 11:995. doi:10.12688/f1000-research.125050.1. pmid: 37128216
[16]	Meledathu S, Gordon M, Thornton M, et al. Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Report and Literature Review[J]. J Drugs Dermatol, 2023, 22(11):e24-e28. doi:10.36849/JDD.6999. pmid: 37943271
[17]	Athimni S, Slouma M, Dhahri R, et al. Tuberculosis Infection Under Anti-TNF Alpha Treatment[J]. Curr Drug Saf, 2022, 17(3):235-240. doi:10.2174/1574886316666211109092354.
[18]	林洁, 周文文, 王珊珊. 依那西普治疗中毒性表皮坏死松解症18例疗效观察及文献复习[J]. 中国医学工程, 2025, 33(12):52-57. doi:10.19338/j.issn.1672-2019.2025.12.009.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wei Daijue, Deng Mingkun, Chen Yan, Yang Zengwei, Tong Chongxiang. Serum expression levels and clinical value of IFN-γ, IL-2 and IL-6 in elderly pulmonary tuberculosis patients aged 60 years and older [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1170-1175.
[2]	Lyu Yongyun, Li Xiaoqin, Wu Mengtai, Zhou Min, Tian Nan, Shen Ling. Study on hospitalization cost and its influencing factors of pulmonary tuberculosis under the diagnosis-related group payment model [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1205-1213.
[3]	Qi Yunfeng, Wang Xueyu, Kang Wanli, Nie Wenjuan, Wang Yiwen. The application value of tongue swab nucleic acid testing in the diagnosis of suspected tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1163-1169.
[4]	Guo Jinlong, Min Xuhong, Song Biao, Li Yuan, Wang Shanghu, Chen Wu. Imaging feature analysis of pseudo-pulmonary embolism on dual-phase computed tomography angiography in pulmonary tuberculosis patients with bronchial-pulmonary shunts [J]. Chinese Journal of Antituberculosis, 2026, 48(8): 1192-1198.
[5]	. [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1073-1076.
[6]	Jiao Xiaoke, Dong Kexin, Yang Xinliang, Nie Wenjuan. Risk factors for QTc interval >500 ms in patients with rifampicin-resistant tuberculosis treated with bedaquiline-containing regimens [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 992-999.
[7]	Feng Yinping, Luo Shuirong, Liu Zhongda, Zhang Zunjing. An association study of the comorbidity spectrum and core traditional Chinese medicine syndromes in 832 elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1038-1043.
[8]	You Jicun, Tian Lei, Wang Lingyan, Yang Zhongrong, Shen Jianyong, Chen Bin. Analysis of latent tuberculosis infection prevalence and its related factors in 1007 patients with diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 965-971.
[9]	Zhang Ji, Zhao Wei, Zhang Zhiyu, Ji Liqin, Zhao Jie. Investigation and analysis of a tuberculosis cluster outbreak in a primary psychiatric hospital [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 972-977.
[10]	Zhao Liping, Zong Xingyu, Cao Yuqing, Jiang Hui, Cai Qiujie, Ma Yan, Mu Tingting, Liu Xiaoming, Liu Bin, Liang Bowen, Cao Yanhua, Li Bo, Luo Jingyue, Wang Guirong, Huang Mailing. Adjuvant therapy with Zhonghe Decoction for abscess lymph node tuberculosis with Qi and blood deficiency syndrome: a randomized controlled trial on short-term efficacy [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1044-1050.
[11]	Chen Yina, Li Weidan, Zhu Kaiqiang, Tang Huiling. Serfling regression model for analyzing tuberculosis epidemiological characteristics in Jinhua City,Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 941-947.
[12]	Li Jike, Luo Mei, Zou Liping, Ye Qing, Luo Xiangyi, Gong Mengmeng, Zhang Huifang, Cao Yuqing, Fu Xiaoyan, Feng Xia, Zhou Xiaolong, Yang Yingmei, Pang Wenxiao, Ma Yan, Wu Guihui. Clinical study on adjuvant therapy of oral and external traditional Chinese medicine for abdominal tuberculosis complicated with intestinal obstruction [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 1030-1037.
[13]	Liu Jia, Tan Jing, Tian Yao, Fu Manjiao, Liu Huimin, Chen Hongmei, Zhai An, Kang Yi, Chen Liang, Bei Chengli. Risk factors and predictive model for poor prognosis among HIV-negative patients with disseminated tuberculosis admitted to intensive care unit [J]. Chinese Journal of Antituberculosis, 2026, 48(7): 933-940.
[14]	Xia Lu, Mu Tingting, Cai Qiujie, Ma Yan, Gong Mengmeng, Ye Dan, Zhang Wei. Analysis of Traditional Chinese Medicine syndrome characteristics in 619 severe pulmonary tuberculosis patients based on syndrome element differentiation [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 795-802.
[15]	Wang Xinyan, Pan Hongfang, Mei Xue, Zhang Yi, Liu Jie. Analysis of the characteristics of peripheral blood clinical detection indicators in patients with pulmonary tuberculosis complicated with osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 779-786.